Infective Endocarditis — Written Clinical Reasoning

SAQ 1 — Integrated Management (25 marks, 35 minutes)

Prompt: Outline your integrated management plan for this patient, including the problem list, Modified Duke criteria classification, immediate investigations, antibiotic regimen, surgical decision, anticoagulation management, and complication surveillance. Justify each decision with reference to evidence and guidelines. [1]

Model Answer

Problem list (3 marks):

1. Prosthetic valve infective endocarditis (mechanical mitral valve) due to methicillin-sensitive Staphylococcus aureus — definite by Duke criteria
2. New paravalvular regurgitation with pulmonary oedema — heart failure, potential surgical indication
3. Transient ischaemic attack / embolic event 3 days ago — neurological complication
4. Acute kidney injury (creatinine 145, baseline 90) — multifactorial
5. Atrial fibrillation (rate 96) — likely chronic given mechanical valve
6. Anticoagulation management — warfarin for mechanical valve in the setting of IE and recent embolic event [1]

Modified Duke classification (2 marks): This patient has definite IE:

• Major 1: typical organism (Staphylococcus aureus) in blood cultures from three separate sites
• Major 2: echo evidence of endocardial involvement (vegetation on prosthetic mitral valve with new paravalvular regurgitation)
• Minor: predisposition (prosthetic valve), fever (38.6 degrees), vascular phenomena (Janeway lesions — painless palmar macules), immunological phenomena (Osler node — painful finger pad nodule) [1]

Two major criteria establish definite IE. Note that Staphylococcus aureus bacteraemia is itself a Duke major criterion regardless of whether a primary focus is identified (Li et al, 2000, PMID 10770721). [1]

Immediate investigations (3 marks):

1. Transoesophageal echocardiography (TOE) — mandatory in all prosthetic valve IE and in any case with suspected paravalvular complication. TTE has low sensitivity for PVE. TOE will define the vegetation, assess for paravalvular abscess, dehiscence, fistula, and evaluate the severity and mechanism of regurgitation.
2. ECG monitoring — continuous telemetry to detect new conduction block (PR prolongation, bundle branch block, complete heart block), which would indicate paravalvular abscess extension into the conducting system.
3. CT head — to characterise the neurological event (TIA vs completed infarct vs haemorrhage), which critically influences the timing of any surgery. CT angiography of cerebral vessels if mycotic aneurysm suspected.
4. Repeat blood cultures — to document clearance and guide duration of therapy.
5. Dental review — to identify the portal of entry for oral streptococci (though this is Staphylococcus aureus, suggesting a different source — IV line, skin, healthcare exposure). [1]

Antibiotic regimen (4 marks): Empiric therapy was appropriate — MSSA is sensitive to flucloxacillin. For prosthetic valve staphylococcal endocarditis, the regimen is:

• Flucloxacillin 2 g IV 4-hourly (12 g/day) for at least 6 weeks
• PLUS Rifampicin 300-600 mg IV/PO daily — added only AFTER bacteraemia has cleared (usually 3-5 days) to avoid rapid emergence of resistance; rifampicin is essential for sterilising the biofilm on prosthetic material
• PLUS Gentamicin 1 mg/kg IV TDS (low dose for synergy) for the first 2 weeks — though in this patient with AKI, gentamicin should be used cautiously or withheld, as the risk of further nephrotoxicity is significant [1]

Note the regional delta: ANZ Therapeutic Guidelines and ESC 2023 (PMID 37470749) support this triple regimen for staphylococcal PVE. Rifampicin induces warfarin metabolism significantly — INR will fall and warfarin dose will need substantial upward adjustment, or conversion to heparin. [1]

Surgical decision (6 marks): This patient has multiple surgical indications and should be referred urgently to the Endocarditis Team and cardiac surgery:

1. Heart failure — the strongest indication. New paravalvular regurgitation causing pulmonary oedema, elevated JVP, and bibasal crackles. Heart failure from a surgically correctable valvular lesion mandates surgery (Baddour et al, 2005, PMID 15956145; ESC 2023, PMID 37470749).
2. Prosthetic valve IE with Staphylococcus aureus — PVE with S. aureus has high medical-therapy failure rates; early surgery is generally favoured.
3. New paravalvular regurgitation — suggests possible paravalvular dehiscence, which is a mechanical complication requiring surgical correction.
4. Embolic event — the recent TIA indicates active embolisation, further supporting early surgery. [1]

The timing of surgery is modified by the neurological event. If the CT head shows a TIA with no infarct, surgery can proceed. If there is an ischaemic infarct, surgery is ideally deferred 2-4 weeks because of the risk of haemorrhagic transformation under cardiopulmonary bypass. If there is haemorrhagic transformation, surgery is deferred 4 weeks. However, if heart failure is refractory and life-threatening, early surgery may proceed after neurosurgical consultation — the mortality of deferring exceeds the neurological risk. [1]

The Kang et al (2012, PMID 22738096) RCT supports early surgery for large vegetations with embolic risk, though it excluded patients with stroke and PVE. [1]

Anticoagulation management (3 marks): This patient has a mechanical mitral valve requiring lifelong anticoagulation. In the setting of IE with a recent embolic event and planned surgery:

1. Stop warfarin and convert to unfractionated heparin infusion (short half-life, fully reversible) — this allows rapid reversal before surgery and rapid re-establishment after.
2. Monitor INR to below 1.5 before surgery (typically target INR below 1.5 for cardiac surgery).
3. Beware rifampicin-warfarin interaction — rifampicin is a potent hepatic enzyme inducer that markedly increases warfarin clearance. If warfarin is continued postoperatively, the dose will need to be approximately doubled or tripled. Heparin avoids this issue during the rifampicin phase.
4. Do not switch to a DOAC — mechanical valves require warfarin; DOACs are contraindicated (RE-ALIGN trial showed harm with dabigatran in mechanical valves). [1]

Complication surveillance (2 marks):

• Daily clinical assessment for heart failure, embolic events, new murmurs
• Serial ECG for conduction block (paravalvular abscess)
• Repeat TOE if clinical deterioration, persistent fever, new conduction block, or before surgery
• Renal function and electrolytes daily (AKI monitoring, especially if gentamicin used)
• Repeat blood cultures every 48 hours until clear, then weekly
• Temperature charting daily; persistent fever beyond 5-7 days of appropriate therapy suggests uncontrolled infection or metastatic focus [1]

Communication and follow-up (2 marks):

• Endocarditis Team referral immediately (cardiology, infectious diseases, cardiac surgery, microbiology)
• Discuss surgical risk with patient and family — PVE surgery carries 5-15% operative mortality
• Counsel on prolonged IV antibiotic course (6 weeks minimum), likely via PICC line and OPAT
• Dental review to identify portal of entry
• Screen for healthcare-associated source (recent IV lines, procedures)
• Post-treatment: echocardiographic surveillance, lifelong prophylaxis (already high-risk), education on recurrence symptoms [1]

SAQ 2 — Prophylaxis Decision-Making (10 marks, 15 minutes)

Prompt: A 30-year-old woman with a history of infective endocarditis at age 25 (treated medically, native mitral valve) presents to her general practitioner requesting antibiotic prophylaxis before a routine gastroscopy and colonoscopy for investigation of iron deficiency anaemia. She has no residual valvular disease. She is penicillin-allergic (rash only, no anaphylaxis). Outline your advice regarding infective endocarditis prophylaxis, including the specific recommendations and the evidence base. [1]

Model Answer

Risk classification (2 marks): This patient is in the HIGH-RISK group for infective endocarditis because she has a history of previous IE — this is one of the four high-risk categories identified by the AHA 2007 guideline (Wilson et al, PMID 17446442) and the 2023 ESC guideline (PMID 37470749). The other categories are prosthetic valve, specified congenital heart disease, and cardiac transplant valvulopathy (AHA only). Previous IE confers the highest risk of recurrence. [1]

Procedures — which warrant prophylaxis? (4 marks):

• Routine gastroscopy and colonoscopy do NOT require IE prophylaxis, even in high-risk patients. The AHA, ESC, and NICE all agree on this. The evidence shows that bacteraemia from these procedures is low-grade and transient, and that prophylaxis has not been shown to prevent IE.
• Prophylaxis is restricted to dental procedures involving manipulation of gingival tissue, the periapical region of teeth, or perforation of the oral mucosa (extractions, scaling, periodontal procedures).
• Procedures involving infected tissue (drainage of abscess at any site) may warrant prophylaxis covering the infecting organism, but this is treatment of infection, not IE prophylaxis per se. [1]

The procedure she actually needs — investigation of iron deficiency (2 marks): She should proceed with the gastroscopy and colonoscopy without IE prophylaxis. The iron deficiency anaemia itself requires investigation — but not for IE reasons. The anaemia may be relevant to her overall cardiac risk if she had residual valve disease, but she has been cleared on echo. [1]

Her penicillin allergy — what does it mean? (1 mark): Her non-anaphylactic penicillin allergy (rash) would, if she needed dental prophylaxis, allow cephalexin 2 g PO or clindamycin 600 mg PO. But she does not need prophylaxis for this GI procedure, so the allergy is moot for this encounter. Document it accurately for future dental work. [1]

Counselling points (1 mark):

• Explain that her previous IE puts her in a high-risk group, but that modern guidelines restrict prophylaxis to dental procedures, not GI procedures.
• Advise her to maintain meticulous dental hygiene (brushing, flossing, regular dental review every 6 months), as poor dentition is the most important modifiable risk factor for IE in high-risk patients.
• For future dental procedures (extractions, scaling, periodontal work), she WILL need prophylaxis — amoxicillin 2 g PO 60 minutes before, or cephalexin 2 g PO (given her non-anaphylactic penicillin allergy).
• The NICE CG64 guideline (UK) recommends NO routine prophylaxis at all, but the AHA and ESC (and ANZ practice) recommend prophylaxis for high-risk patients undergoing dental procedures — this is the standard she should follow. [1]